📊 TCRT Key Takeaways
Is Alaunos Therapeutics, Inc. (TCRT) a Good Investment?
Alaunos is a pre-revenue company with zero sales and $1M annual operating losses, facing critical cash depletion within 3-4 months at current burn rates. Without immediate capital injection or dramatic operational changes, the company faces potential insolvency. The slight improvement in loss trends (EPS improving 24.7% YoY) is insufficient to offset the existential liquidity crisis.
Alaunos Therapeutics, Inc. Key Strengths (TCRT)
- No long-term debt on balance sheet
- Current ratio of 1.63x provides short-term liquidity buffer
- Loss per share trend improving YoY (shrinking losses)
TCRT Stock Risks: Alaunos Therapeutics, Inc. Investment Risks
- Critical cash runway: $354K cash with $1M+ annual burn = ~3-4 months of operations remaining
- Zero revenue and 50% YoY revenue decline indicates no viable commercial operations
- Negative ROE (-78.1%) and ROA (-53.4%) demonstrate fundamental unprofitability
- Imminent need for emergency capital raise or dilutive financing
- Pharma sector with no disclosed revenue-generating products or pipeline value
Key Metrics to Watch
- Cash and equivalents depletion rate and runway to insolvency
- Capital raise activity and terms (Form D filings, shelf registrations)
- Quarterly burn rate and operating expense trends
- Any revenue-generating activities or partnership announcements
Alaunos Therapeutics, Inc. (TCRT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Alaunos Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
TCRT Profit Margin, ROE & Profitability Analysis
TCRT vs Healthcare Sector: How Alaunos Therapeutics, Inc. Compares
How Alaunos Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Alaunos Therapeutics, Inc. Stock Overvalued? TCRT Valuation Analysis 2026
Based on fundamental analysis, Alaunos Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Alaunos Therapeutics, Inc. Balance Sheet: TCRT Debt, Cash & Liquidity
TCRT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Alaunos Therapeutics, Inc.'s revenue has declined by 97% over the 5-year period, indicating business contraction. The most recent EPS of $-2.92 indicates the company is currently unprofitable.
TCRT Revenue Growth, EPS Growth & YoY Performance
TCRT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$1.0M | $-0.59 |
| Q3 2025 | N/A | -$1.1M | $-0.55 |
| Q2 2025 | N/A | -$1.1M | $-0.63 |
| Q1 2025 | $1.0K | -$1.1M | $-0.67 |
| Q3 2024 | N/A | -$1.1M | $-0.70 |
| Q2 2024 | $4.0K | -$1.1M | $-0.71 |
| Q1 2024 | N/A | -$1.7M | $-0.11 |
| Q3 2023 | N/A | -$8.5M | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Alaunos Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TCRT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Alaunos Therapeutics, Inc. (CIK: 0001107421)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TCRT
What is the AI rating for TCRT?
Alaunos Therapeutics, Inc. (TCRT) has an AI grade of D with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TCRT's key strengths?
Claude: No long-term debt on balance sheet. Current ratio of 1.63x provides short-term liquidity buffer.
What are the risks of investing in TCRT?
Claude: Critical cash runway: $354K cash with $1M+ annual burn = ~3-4 months of operations remaining. Zero revenue and 50% YoY revenue decline indicates no viable commercial operations.
What is TCRT's revenue and growth?
Alaunos Therapeutics, Inc. reported revenue of $0.0.
Does TCRT pay dividends?
Alaunos Therapeutics, Inc. does not currently pay dividends.
Where can I find TCRT SEC filings?
Official SEC filings for Alaunos Therapeutics, Inc. (CIK: 0001107421) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TCRT's EPS?
Alaunos Therapeutics, Inc. has a diluted EPS of $-0.59.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TCRT's fundamental grade?
Based on our AI fundamental analysis in June 2026, Alaunos Therapeutics, Inc. has a D grade with 95% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TCRT stock overvalued or undervalued?
Valuation metrics for TCRT: ROE of -78.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TCRT's AI grade for 2026?
Our dual AI analysis gives Alaunos Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TCRT's free cash flow?
Alaunos Therapeutics, Inc.'s operating cash flow is $-1.0M, with capital expenditures of $98.0K.
How does TCRT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -78.1% (avg: 15%), current ratio 1.63 (avg: 2).